Therefore, α‐Mangostin has an additional clinical advantage, that is, if the pancreatic cancer patients develop resistance to smoothened inhibition due to mutation(s) on the smoothened receptors, they will be able to respond to α‐Mangostin because it also inhibits the expression of effector molecule Gli. This evidence concerns the gene GLI1 and familial pancreatic carcinoma.